SME Times is powered by   
Search News
Just in:   • Indian equity indices end slightly lower ahead of RBI's MPC outcome  • J&K’s Kishtwar selected as aspirational agricultural district under PMDDKY  • Indian stock market opens higher as RBI MPC begins  • Mumbai-Ahmedabad bullet train to be fully operational by 2029: Ashwini Vaishnaw  • Nifty, Sensex see sharp decline this week amid H-1B, pharma tariff concerns 
Last updated: 01 Feb, 2017  

cadila.thumb.jpg Cadila Healthcare net profit declines 34.6 pc in Q3

cadila.jpg
   Top Stories
» Indian equity indices end slightly lower ahead of RBI's MPC outcome
» Indian stock market opens higher as RBI MPC begins
» Mumbai-Ahmedabad bullet train to be fully operational by 2029: Ashwini Vaishnaw
» Nifty, Sensex see sharp decline this week amid H-1B, pharma tariff concerns
» Govt stands shoulder to shoulder with entrepreneurs, PM Modi pitches ‘Make in India’ at UP trade show
SME Times News Bureau | 01 Feb, 2017
Global pharmaceutical company Cadila Healthcare on Tuesday posted a 34.6 percent decline in its consolidated net profit to Rs 281.6 crore for the quarter ended December 31, 2016 as compared with Rs 430.5 crore in the year-ago period.

The company's consolidated total income from operations also dipped to Rs 2,363.8 crore during the quarter under review as compared with Rs 2,408.9 crore in a year-ago period.

On BSE, the stock settled at Rs 349.25, down 7.02 percent from the previous close.
 
Print the Page Add to Favorite
 
Share this on :
 

Please comment on this story:
 
Subject :
Message:
(Maximum 1500 characters)  Characters left 1500
Your name:
 

 
  Customs Exchange Rates
Currency Import Export
US Dollar
₹84.00
₹82.25
UK Pound
₹104.65
₹108.10
Euro
₹92.50
₹89.35
Japanese Yen ₹56.10 ₹54.40
As on 25 Jul, 2025
  Daily Poll
Who do you think will benefit more from the India - UK FTA in the long run?
 Indian businesses & consumers.
 UK businesses & consumers.
 Both will gain equally.
 The impact will be negligible for both.
  Commented Stories
 
 
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter